Agios Pharmaceuticals Inc (NASDAQ:AGIO) agreed to sell its rights to its 15% royalty on potential U.S. net sales of Servier’s ...

Agios Pharmaceuticals (NASDAQ:AGIO) announced an agreement with Royalty Pharma (NASDAQ:RPRX) to sell its 15% royalty on ...

Royalty Pharma plc (RPRX) announced Tuesday that it has acquired an interest in Agios Pharmaceuticals' (AGIO) royalty on Servier's ...

Royalty Pharma to Acquire Rights to Agios’ 15% Royalty on Potential Vorasidenib U.S. Net Sales for $905 Million Upfront upon FDA Approval of ...

Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock is soaring today, after news that Royalty Pharma (RPRX) is buying partial royalty rights on potential U.S. net sales of the biotech name's brain tumor ...

Shares of Agios Pharmaceuticals (AGIO) have gained 3.2% over the past four weeks to close the last trading session at $32.69, but there could still be a solid upside left in the stock if short ...

Agios Pharmaceuticals Inc (NASDAQ: AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary Vandana ...

Agios Pharmaceuticals AGIO reported a loss of $1.45 per share in first-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of $1.64. In the year-ago quarter, the company reported a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...